MedTrace Logo

The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A

NCT05587699 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2024-01-22

No results posted yet for this study

Summary

A study to evaluate the pharmacokinetics, pharmacodynamics, and safety of CKD-843 A in male subjects.

Conditions

Interventions

DRUG

CKD-843 A 45mg(Multiple dose)

1 Injection/3 Month, 3 times Injections

DRUG

CKD-843 A 45mg

Single Injection

DRUG

CKD-843 A 55mg(Multiple dose)

1 Injection/3 Month, 3 times Injections

DRUG

CKD-843 A 55mg

Single Injection

DRUG

CKD-843-R

0.5mg/day, 9 Month

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Minsoo Park, M.D., Ph.D · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2023-09-15
Completion
2023-10-17

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05587699 on ClinicalTrials.gov